Generation bio announces strategic reorganization to extend cash runway for development of ctlnp and iqdna platforms

Cambridge, mass., nov. 29, 2023 (globe newswire) -- generation bio co. (nasdaq:gbio), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctlnp) delivery system for wholly-owned programs in extrahepatic cell types. generation bio intends to continue to develop ctlnp for immune cells as part of its collaboration with moderna and to develop its immune-quiet dna (iqdna) for its lead hemophilia a and other programs.
GBIO Ratings Summary
GBIO Quant Ranking